Volume 18, Number 9—September 2012
Dispatch
Rapid Detection of Carbapenemase-producing Enterobacteriaceae
Patrice Nordmann
, Laurent Poirel, and Laurent Dortet
, Laurent Poirel, and Laurent Dortet
Table 2
Non–carbapenemase-producing clinical enterobacterial isolates subjected to the Carba NP test*
| β-Lactamase type, species | β-Lactamase | No. | MIC, mg/L |
Carba NP test result | ||
|---|---|---|---|---|---|---|
| IMP | ERT | MER | ||||
| ESBLs | ||||||
| Klebsiella pneumoniae | CTX-M-3 | 1 | 0.12 | 0.12 | 0.12 | – |
| CTX-M-14 | 1 | 0.12 | 0.12 | 0.12 | – | |
| CTX-M-15 | 3 | 0.12 | 0.12 | 0.12 | – | |
| Escherichia coli | CTX-M-1 | 1 | 0.12 | 0.12 | 0.12 | – |
| CTX-M-3 | 1 | 0.12 | 0.12 | 0.12 | – | |
| CTX-M-14 | 2 | 0.12 | 0.12 | 0.12 | – | |
| CTX-M-15 | 2 | 0.12 | 0.12 | 0.12 | – | |
| VEB-1 | 1 | 0.12–0.25 | 0.12 | 0.12 | – | |
| Enterobacter cloacae | CTX-M-15 | 3 | 0.12 | 0.12 | 0.12 | – |
| VEB-1 |
1 |
0.12 |
0.12 |
0.12 |
– |
|
| Plasmid-mediated AmpC or chromosomal AmpC + decreased membrane permeability | ||||||
| K. pneumoniae | DHA-1 | 1 | >32 | >32 | >32 | – |
| DHA-2 | 1 | 0.12 | 0.5 | 0.12 | – | |
| E. coli | Extended-spectrum cephalosporinase | 1 | 0.12 | 0.12 | 0.12 | – |
| CMY-2 | 1 | 0.12 | 0.12 | 0.12 | – | |
| CMY-10 | 1 | 0.12 | 0.38 | 0.12 | – | |
| DHA-1 | 1 | 0.12 | 0.12 | 0.12 | – | |
| ACC-1 | 1 | 0.12 | 0.12 | 0.12 | – | |
| Overexpressed cephalosporinase | 1 | 16 | >32 | 2 | – | |
| Proteus mirabilis | ACC-1 | 1 | 0.25 | 0.12 | 0.12 | – |
| E. cloacae | Overexpressed cephalosporinase | 7 | 0.12–16 | 1–>32 | 0.12–>32 | – |
| Enterobacter aerogenes | Overexpressed cephalosporinase | 1 | 1 | 4 | 0.75 | – |
| Morganella morganii |
Overexpressed cephalosporinase |
2 |
1.5–2 |
0.12 |
0.5 |
– |
| ESBL + decreased membrane permeability | ||||||
| K. pneumoniae | CTX-M-15 | 8 | 0.25–8 | 1–>32 | 1–>32 | – |
| SHV-28 | 1 | 1 | 4 | 1 | – | |
| SHV-2a | 1 | 0.25 | 2 | 0.38 | – | |
| Enterobacter sakazakii | CTX-M-15 | 1 | 0.25 | 1.5 | 0.25 | – |
| Citrobacter freundii | TEM-3 | 1 | 1 | 8 | 1 | – |
*IMP, imipenem; ERT, ertapenem; MER, meropenem; ESBLs, extended-spectrum β-lactamases.
Page created: August 27, 2012
Page updated: August 27, 2012
Page reviewed: August 27, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.